𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oxaliplatin, fluorouracil and leucovorin (FOLFOX) as first-line chemotherapy for metastatic or recurrent colorectal cancer patients

✍ Scribed by Han, Bing ;Xu, Ruihua ;Shi, Yanxia ;Luo, Huiyan ;Xiang, Xiaojuan ;Li, Yuhong ;Zhang, Li ;Lin, Tongyu ;He, Youjian

Book ID
107513108
Publisher
Springer-Verlag
Year
2007
Weight
445 KB
Volume
4
Category
Article
ISSN
1672-7118

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capecitabine plus oxaliplatin (XELOX) ve
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF

Fluorouracil, Leucovorin, and Oxaliplati
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 201 KB

## Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation sta